Abstract:Cancer is a significant health hazard of the 21st century, and GLOBOCAN predicts increasing cancer incidence in the coming decades. Though several conventional treatment modalities exist, most of them end up causing off-target and debilitating effects, and drug resistance acquisition. Advances in our understanding of tumor molecular biology offer alternative strategies for precise, robust, and potentially less toxic treatment paradigms for circumventing the disease at the cellular and molecular level. Several deregulated molecules associated with tumorigenesis have been developed as targets in RNA interference (RNAi) based cancer therapeutics. RNAi, a post-transcriptional gene regulation mechanism, has significantly gained attention because of its precise multi-targeted gene silencing. Although the RNAi approach is favorable, the direct administration of small oligonucleotides has not been fruitful because of their inherent lower half-lives and instability in the biological systems. Moreover, the lack of an appropriate delivery system to the primary site of the tumor that helps determine the potency of the drug and its reach, has limited the effective medical utilization of these bio-drugs. Nanotechnology, with its unique characteristics of enhanced permeation and better tumor-targeting efficiency, offers promising solutions owing to the various possibilities and amenability for modifications of the nanoparticles to augment cancer therapeutics. Nanoparticles could be made multimodal, by designing and synthesizing multiple desired functionalities, often resulting in unique and potentially applicable biological structures. A small number of Phase I clinical trials with systemically administered siRNA molecules conjugated with nanoparticles have been completed and the results are promising, indicating that, these new combinatorial therapies can successfully and safely be used to inhibit target genes in cancer patients to alleviate some of the disease burden. In this review, we highlight different types of nano-based delivery strategies for engineering Nano-RNAi-based bio drugs. Furthermore, we have highlighted the insights gained from current research that are entering the preclinical evaluation and information about initial clinical developments, shaping the future for next generation cancer therapeutics.

Emerging role of RNA interference in immune cells engineering and its therapeutic synergism in immunotherapy.

RNA interference mediated by oncolytic viruses in tumor therapy

RNA Cancer Nanomedicine: Nanotechnology-Mediated RNA Therapy.

Emerging role of RNA sensors in tumor microenvironment and immunotherapy

RNAi-mediated Gene Silencing in Cancer Therapy

RNA Nanotechnology-Mediated Cancer Immunotherapy

RNA and RNA derivatives: light and dark sides in cancer immunotherapy

Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers

An update on RNA interference-mediated gene silencing in cancer therapy.

Recent Advances in RNA-Targeted Cancer Therapy

Enhancing Chemotherapy by RNA Interference

Insight Into the Prospects for RNAi Therapy of Cancer

Emerging Progress of RNA-Based Antitumor Therapeutics

The role of RNA methylation in tumor immunity and its potential in immunotherapy

Interfering with Disease: Opportunities and Roadblocks to Harnessing RNA Interference

Therapeutic Potentials of Gene Silencing by RNA Interference: Principles, Challenges, and New Strategies.

Novel Insight into RNA Modifications in Tumor Immunity: Promising Targets to Prevent Tumor Immune Escape

RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics

Rna Interference: A Potent Tool for Gene-Specific Therapeutics

RNA-Based Therapeutics: Past, Present and Future Prospects, Challenges in Cancer Treatment

RNA Interference and Nanotechnology: A Promising Alliance for Next Generation Cancer Therapeutics